Dr. Altman's research is focused on increasing understanding of the role of aberrant signal transduction pathways in the development of myeloid neoplasms; defining molecular targets for the treatment of leukemias; and generating clinical trials based on such research work. With extensive experience in translational work in this area, she actively participated in work to define the roles mTOR and Mnk pathways in the generation of anti-leukemic responses in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).